PMID- 23661613
OWN - NLM
STAT- MEDLINE
DCOM- 20131030
LR  - 20211021
IS  - 1097-0045 (Electronic)
IS  - 0270-4137 (Print)
IS  - 0270-4137 (Linking)
VI  - 73
IP  - 13
DP  - 2013 Sep
TI  - Immunohistochemical expression of ERG in the molecular epidemiology of fatal 
      prostate cancer study.
PG  - 1371-7
LID - 10.1002/pros.22684 [doi]
AB  - BACKGROUND: Gene fusions between the ERG transcription factor and the 
      androgen-regulated gene TMPRSS2 occur in a subset of prostate cancers and 
      contribute to transformation of prostatic epithelial cells. Prior reports have 
      used fluorescence in situ hybridization (FISH) or quantitative PCR (QPCR) to 
      determine the presence of TMPRSS2-ERG fusions or ERG expression, respectively. 
      Recently, several groups have reported on immunohistochemistry (IHC) to measure 
      ERG expression, which is much more readily performed in clinical practice. 
      However, the prior studies examining ERG expression by IHC had small sample sizes 
      or they failed to clarify the association of ERG protein expression with 
      important clinico-pathological features or prostate cancer-specific mortality. 
      METHODS: To address these deficits, we evaluated ERG expression by IHC in 208 
      radical prostatectomy samples from the Kaiser Permanente Molecular Epidemiology 
      of Fatal Prostate Cancer (MEFPC) study, a case-control study of prostate 
      cancer-specific mortality. RESULTS: Nuclear ERG expression was seen in neoplastic 
      prostate epithelia in 49 of the samples (23.7%). ERG expression in tumor cells 
      was associated with higher tumor stage (OR = 2.0, 95% confidence interval 
      1.0-4.0, P value = 0.04). ERG immunoreactivity was positively associated with 
      prostate cancer-specific mortality, although the confidence interval was wide 
      (OR = 1.9, 95% confidence interval 0.88-4.0, P value = 0.10). CONCLUSIONS: Our 
      results demonstrate that ERG protein expression is readily quantifiable with an 
      existing commercial antibody. Evaluating ERG protein expression may improve our 
      ability to identify the subset of more aggressive, invasive prostate cancers.
CI  - (c) 2013 Wiley Periodicals, Inc.
FAU - Weinmann, Sheila
AU  - Weinmann S
AD  - The Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon 
      97227, USA. Sheila.Weinmann@kpchr.org
FAU - Van Den Eeden, Stephen K
AU  - Van Den Eeden SK
FAU - Haque, Reina
AU  - Haque R
FAU - Chen, Chuhe
AU  - Chen C
FAU - Richert-Boe, Kathryn
AU  - Richert-Boe K
FAU - Schwartzman, Jacob
AU  - Schwartzman J
FAU - Gao, Lina
AU  - Gao L
FAU - Berry, Deborah L
AU  - Berry DL
FAU - Kallakury, Bhaskar V S
AU  - Kallakury BV
FAU - Alumkal, Joshi J
AU  - Alumkal JJ
LA  - eng
GR  - KL2 RR024141/RR/NCRR NIH HHS/United States
GR  - R01 CA100743/CA/NCI NIH HHS/United States
GR  - UL1 RR024140/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20130509
PL  - United States
TA  - Prostate
JT  - The Prostate
JID - 8101368
RN  - 0 (ERG protein, human)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (TMPRSS2-ERG fusion protein, human)
RN  - 0 (Trans-Activators)
RN  - 0 (Transcriptional Regulator ERG)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Case-Control Studies
MH  - Humans
MH  - Immunohistochemistry
MH  - Male
MH  - Middle Aged
MH  - Oncogene Proteins, Fusion/*metabolism
MH  - Prostate/*metabolism/pathology/surgery
MH  - Prostatectomy
MH  - Prostatic Neoplasms/*metabolism/*mortality/pathology
MH  - Trans-Activators/*metabolism
MH  - Transcriptional Regulator ERG
PMC - PMC3745520
MID - NIHMS469395
OTO - NOTNLM
OT  - biomarker
OT  - case-control
OT  - lethal prostate cancer
COIS- Conflict of Interest Statement: There are no conflicts of interest to disclose.
EDAT- 2013/05/11 06:00
MHDA- 2013/10/31 06:00
PMCR- 2014/09/01
CRDT- 2013/05/11 06:00
PHST- 2012/11/21 00:00 [received]
PHST- 2013/04/08 00:00 [accepted]
PHST- 2013/05/11 06:00 [entrez]
PHST- 2013/05/11 06:00 [pubmed]
PHST- 2013/10/31 06:00 [medline]
PHST- 2014/09/01 00:00 [pmc-release]
AID - 10.1002/pros.22684 [doi]
PST - ppublish
SO  - Prostate. 2013 Sep;73(13):1371-7. doi: 10.1002/pros.22684. Epub 2013 May 9.